QT
RVNC

Quantamental Technologies’s Revance Therapeutics, Inc. RVNC Stock Holding History

Quantamental Technologies’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,742
Closed -$62K – 1406
2019
Q3 		$62K Buy
4,742
+3,199
+207% +$39.1K 0.02% 896
2019
Q2 		$20K Buy
+1,543
New +$19.4K 0.01% 1133

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Quantamental Technologies's RVNC Position: Q4 2019 in Review

Quantamental Technologies sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2019, closing a stake of 4,742 shares — an estimated $62K sold.

Quantamental Technologies first reported a position in RVNC in Q2 2019 and held it in 2 quarters. The position peaked at $62K in Q3 2019. 134 funds tracked by Wall St. Rank hold RVNC as of Q4 2019.

  • Quantamental Technologies reported no remaining Revance Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Quantamental Technologies sold 4,742 Revance Therapeutics, Inc. shares in Q4 2019, an estimated $62K.
  • Quantamental Technologies first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 2 quarters.
  • Quantamental Technologies's Revance Therapeutics, Inc. position peaked at $62K in Q3 2019.
  • 134 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2019.

Based on Quantamental Technologies's 13F filing for Q4 2019, filed 14 Feb 2020.